Literature DB >> 28092395

Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.

Matthew D Karl, Jasmine H Francis, Saipriya Iyer, Brian Marr, David H Abramson.   

Abstract

PURPOSE: To investigate the impact of intravitreal chemotherapy on intraocular pressure (IOP) in children with retinoblastoma.
METHODS: This was a retrospective study of 10 eyes of 10 patients with retinoblastoma (7 males, 3 females, mean age: 33.6 ± 9.4 months) with vitreous seeding injected with intravitreal melphalan and topotecan. IOP was measured with Tonopen (Reichert, Inc., Buffalo, NY) at baseline prior to injecting and then repeatedly following each intravitreal injection.
RESULTS: Mean pre-injection IOP was 8.2 ± 2.3 mm Hg (range: 4 to 12 mm Hg). Mean IOP 1 to 30 seconds after intravitreal melphalan (first injection) was 45.4 ± 14.3 mm Hg. The IOP of 89.5% of patients declined to 29 mm Hg or less in a mean 153.3 ± 97.5 seconds. Mean IOP 1 to 30 seconds after intravitreal topotecan (second injection) was 44.5 ± 11.0 mm Hg, which decreased to 31.0 ± 5.0 mm Hg by 150 seconds after injection. No significant relationship was found between age and post-injection IOP elevation. IOP exceeded the calculated mean arterial perfusion pressure in four encounters.
CONCLUSIONS: Intravitreal chemotherapy caused a transient rise in IOP. Post-injection IOP elevations can reach levels that may exceed mean arterial pressure. [J Pediatr Ophthalmol Strabismus. 2017;54(3):185-190.]. Copyright 2017, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28092395      PMCID: PMC5473509          DOI: 10.3928/01913913-20161116-01

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  38 in total

1.  Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.

Authors:  Judy E Kim; Anand V Mantravadi; Elizabeth Y Hur; Douglas J Covert
Journal:  Am J Ophthalmol       Date:  2008-09-05       Impact factor: 5.258

2.  Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.

Authors:  Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

3.  Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.

Authors:  Matthias Fuest; Konstantin Kotliar; Peter Walter; Niklas Plange
Journal:  Ophthalmic Physiol Opt       Date:  2014-04-14       Impact factor: 3.117

4.  Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  Matthew S Benz; Thomas A Albini; Eric R Holz; Rohit R Lakhanpal; Andrew C Westfall; Mohan N Iyer; Petros E Carvounis
Journal:  Ophthalmology       Date:  2006-05-02       Impact factor: 12.079

5.  Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir.

Authors:  Patricia Chévez-Barrios; Murali Chintagumpala; William Mieler; Evelyn Paysse; Milton Boniuk; Claudia Kozinetz; Mary Y Hurwitz; Richard L Hurwitz
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

6.  Comparison of Tono-Pen and Goldmann applanation tonometers for measurement of intraocular pressure in healthy children.

Authors:  Yasmin S Bradfield; Brett M Kaminski; Michael X Repka; Michele Melia; Bradley V Davitt; David A Johnson; Raymond T Kraker; Ruth E Manny; Noelle S Matta; Susan Schloff; Katherine K Weise
Journal:  J AAPOS       Date:  2012-03-28       Impact factor: 1.220

7.  Reappraisal of the human ocular growth curve in fetal life, infancy, and early childhood.

Authors:  H C Fledelius; A C Christensen
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

8.  Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma.

Authors:  Jasmine H Francis; David H Abramson; Y Pierre Gobin; Brian P Marr; Irwin Tendler; Scott E Brodie; Ira J Dunkel
Journal:  Ophthalmology       Date:  2015-01-21       Impact factor: 12.079

9.  Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.

Authors:  Jasmine H Francis; Paula Schaiquevich; Emiliano Buitrago; María José Del Sole; Gustavo Zapata; J Oscar Croxatto; Brian P Marr; Scott E Brodie; Alejandro Berra; Guillermo L Chantada; David H Abramson
Journal:  Ophthalmology       Date:  2014-05-10       Impact factor: 12.079

10.  Short-term intraocular pressure changes after intravitreal injection of bevacizumab.

Authors:  Hussein Hollands; Jonathan Wong; Robin Bruen; Robert J Campbell; Sanjay Sharma; Jeffery Gale
Journal:  Can J Ophthalmol       Date:  2007-12       Impact factor: 1.882

View more
  1 in total

1.  Vitreous Disease in Retinoblastoma: Clinical Findings and Treatment.

Authors:  Jasmine H Francis; Larissa A Habib; David H Abramson
Journal:  Adv Ophthalmol Optom       Date:  2017-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.